11 June 2019 in ACS Applied Materials & Interfaces
28 December 2024 in Scientific Reports
Sodium-glucose co-transport protein 2 (SGLT2) inhibitors, a novel category of oral hypoglycemic agents, offer a promising outlook for individuals experiencing heart failure with reduced ejection fraction. Evidence is emerging that highlights their potential in alleviating myocardial fibrosis and oxidative stress. However, the precise mechanisms through which SGLT2 inhibitors influence myocardial fibrosis induced by angiotensin II (Ang II) or transforming growth factor-β1 (TGF-β1) are not fully understood. This study aims to explore the intricate mechanisms by which SGLT2 inhibitors ameliorate myocardial fibrosis, particularly focusing on the nuanced interplay within the SIRT6 signaling pathway. Primary cardiac fibroblasts were isolated from the hearts of 1-3-day-old neonatal KM mice, were stimulated with Ang II or TGF-β1 to establish an in vitro model of myocardial fibrosis. Treatment with 10 µM Empagliflozin (EMPA) and Dapagliflozin (DAPA) significantly curtailed the proliferation of cardiac fibroblasts, substantially reduced collagen expression induced by Ang II/TGF-β1, and mitigated the phenotypic transformation and oxidative stress response. SIRT6, which is closely associated with myocardial fibrosis, demonstrated that the suppression its expression attenuated the protective effects of EMPA and DAPA against myocardial fibrosis and oxidative stress. Our findings suggest that SGLT2 inhibitors markedly decrease the Ang II/TGF-β1-induced transformation of cardiac fibroblasts to a myofibroblast phenotype by upregulating SIRT6 protein expression, thereby inhibiting oxidative stress and ameliorating myocardial fibrosis.
27 July 2021 in ACS Applied Electronic Materials
17 February 2020 in Journal of Ultrasound in Medicine
14 October 2021 in ACS Nano
11 December 2018 in Nanoscale
Nowadays, cold atmospheric plasma (CAP) that contains lots of active free radicals has tremendous potential applications in biomedical engineering, and target delivery of a controllable dose of plasma gas is highly desired in clinical use. In this conceptual study, we developed a novel microbubble loaded by plasma gas and proposed an ultrasound-triggered strategy for the ultrasound-triggered release of free radicals from the microbubbles. The plasma microbubbles (PMBs) were fabricated by mixing plasma gas in the core of the surfactant microbubbles by a modified emulsification process. The resulting PMBs with an average size of 2.54 ± 2.28 μm were successfully fabricated using the proposed approach and the experimental result showed that PMBs exhibited a satisfactory ability to meet the requirement of ultrasound contrast-enhanced imaging. Furthermore, we depicted that ultrasound induced PMB destruction to release the plasma gas and PMBs with ultrasound stimulation could significantly improve the concentration of nitric oxide and hydrogen peroxide compared with the control group. In addition, Dil acting as a model drug was loaded into the PMBs and an in vitro cell experiment showed that Dil and plasma gas could be released from PMBs and internalized by PIEC cells with ultrasound mediation. Our experimental results showed that ultrasound induced PMB destruction could successfully release many active free radicals in plasma gas, including nitric oxide and hydrogen peroxide. The developed novel microbubbles demonstrated the technical potential of plasma gas loaded MBs for disease diagnostics and therapy with ultrasound imaging guidance.